Amgen Beats Earnings Expectations and Expands into Obesity Drug Space

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 32 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 47%
  • Publisher: 63%

Business 뉴스

Amgen,Earnings,Revenue

Amgen reported better-than-expected third-quarter earnings and raised its revenue guidance for the full year. The company recently acquired Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also venturing into the obesity drug market and has completed enrollment for a phase 2 trial for the treatment of obesity.

) reported third-quarter earnings that beat expectations and raised its full-year revenue guidance. The company recently completed its acquisition of Horizon Therapeutics, which brings its drug Tepezza to Amgen. Amgen is also looking to move into the obesity drug space which has garnered much attention from Wall Street.

Shakedown or smart business? Quebec restaurants balk at hefty penalty for using competitor's payment machines Warren Buffett's Japan trade felt like a gift from God, Charlie Munger says: 'It was awfully easy money' TSX energy stocks such as Suncor Energy should be part of your equity portfolio if you are bullish on oil prices in 2023. The post Oil Prices Are Rising: Here Are the Stocks That Will Benefit the Most appeared first on The Motley Fool Canada.Rated lowest margin fees by StockBrokers.com. Borrow against your securities at low cost. Rates subject to change. Your capital is at risk.

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 47. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인

Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.

Amgen Reports 5% Rise in Q3 Product Sales After Horizon Therapeutics AcquisitionAmgen announces a 5% increase in third-quarter product sales, driven by double-digit volume growth but offset by lower prices. The company also raises its post-acquisition sales forecast and adjusted earnings outlook for 2023.
출처: SaltWire Network - 🏆 45. / 63 더 많은 것을 읽으십시오 »